These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 39229272)

  • 1. Unraveling the unphosphorylated STAT3-unphosphorylated NF-κB pathway in loss of function STAT3 Hyper IgE syndrome.
    Karim A; Garg R; Saikia B; Tiwari A; Sahu S; Malhotra M; Minz RW; Rawat A; Singh S; Suri D
    Front Immunol; 2024; 15():1332817. PubMed ID: 39229272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3-Mediated Transcriptional Regulation of Osteopontin in STAT3 Loss-of-Function Related Hyper IgE Syndrome.
    Goel S; Sahu S; Minz RW; Singh S; Suri D; Oh YM; Rawat A; Sehgal S; Saikia B
    Front Immunol; 2018; 9():1080. PubMed ID: 29868029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome.
    Al Khatib S; Keles S; Garcia-Lloret M; Karakoc-Aydiner E; Reisli I; Artac H; Camcioglu Y; Cokugras H; Somer A; Kutukculer N; Yilmaz M; Ikinciogullari A; Yegin O; Yüksek M; Genel F; Kucukosmanoglu E; Baki A; Bahceciler NN; Rambhatla A; Nickerson DW; McGhee S; Barlan IB; Chatila T
    J Allergy Clin Immunol; 2009 Aug; 124(2):342-8, 348.e1-5. PubMed ID: 19577286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation.
    Siegel AM; Stone KD; Cruse G; Lawrence MG; Olivera A; Jung MY; Barber JS; Freeman AF; Holland SM; O'Brien M; Jones N; Nelson CG; Wisch LB; Kong HH; Desai A; Farber O; Gilfillan AM; Rivera J; Milner JD
    J Allergy Clin Immunol; 2013 Dec; 132(6):1388-96. PubMed ID: 24184145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.
    Renner ED; Rylaarsdam S; Anover-Sombke S; Rack AL; Reichenbach J; Carey JC; Zhu Q; Jansson AF; Barboza J; Schimke LF; Leppert MF; Getz MM; Seger RA; Hill HR; Belohradsky BH; Torgerson TR; Ochs HD
    J Allergy Clin Immunol; 2008 Jul; 122(1):181-7. PubMed ID: 18602572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired memory B-cell development and antibody maturation with a skewing toward IgE in patients with STAT3 hyper-IgE syndrome.
    van de Veen W; Krätz CE; McKenzie CI; Aui PM; Neumann J; van Noesel CJM; Wirz OF; Hagl B; Kröner C; Spielberger BD; Akdis CA; van Zelm MC; Akdis M; Renner ED
    Allergy; 2019 Dec; 74(12):2394-2405. PubMed ID: 31269238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Profile of Hyper-IgE Syndrome in India.
    Saikia B; Rawat A; Minz RW; Suri D; Pandiarajan V; Jindal A; Sahu S; Karim A; Desai M; Taur PD; Pandrowala A; Gowri V; Madkaikar M; Dalvi A; Yadav RM; Lashkari HP; Raj R; Uppuluri R; Swaminathan VV; Bhattad S; Cyril G; Kumar H; Shukla A; Kalra M; Govindaraj G; Singh S
    Front Immunol; 2021; 12():626593. PubMed ID: 33717144
    [No Abstract]   [Full Text] [Related]  

  • 8. STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6/STAT3 signalling pathway.
    He J; Shi J; Xu X; Zhang W; Wang Y; Chen X; Du Y; Zhu N; Zhang J; Wang Q; Yang J
    J Biosci; 2012 Jun; 37(2):243-57. PubMed ID: 22581330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SH2-domain mutations in STAT3 in hyper-IgE syndrome patients result in impairment of IL-10 function.
    Giacomelli M; Tamassia N; Moratto D; Bertolini P; Ricci G; Bertulli C; Plebani A; Cassatella M; Bazzoni F; Badolato R
    Eur J Immunol; 2011 Oct; 41(10):3075-84. PubMed ID: 21792878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB.
    Yang J; Liao X; Agarwal MK; Barnes L; Auron PE; Stark GR
    Genes Dev; 2007 Jun; 21(11):1396-408. PubMed ID: 17510282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8(+) T-cell memory formation and function.
    Ives ML; Ma CS; Palendira U; Chan A; Bustamante J; Boisson-Dupuis S; Arkwright PD; Engelhard D; Averbuch D; Magdorf K; Roesler J; Peake J; Wong M; Adelstein S; Choo S; Smart JM; French MA; Fulcher DA; Cook MC; Picard C; Durandy A; Tsumura M; Kobayashi M; Uzel G; Casanova JL; Tangye SG; Deenick EK
    J Allergy Clin Immunol; 2013 Aug; 132(2):400-11.e9. PubMed ID: 23830147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Role of
    Moffitt K; Cheung E; Manis J; Malley R
    Infect Immun; 2018 May; 86(5):. PubMed ID: 29463618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful haploidentical donor hematopoietic stem cell transplant and restoration of STAT3 function in an adolescent with autosomal dominant hyper-IgE syndrome.
    Patel NC; Gallagher JL; Torgerson TR; Gilman AL
    J Clin Immunol; 2015 Jul; 35(5):479-85. PubMed ID: 25962528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3.
    Paulson ML; Freeman AF; Holland SM
    Curr Opin Allergy Clin Immunol; 2008 Dec; 8(6):527-33. PubMed ID: 18978467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells.
    Saito M; Nagasawa M; Takada H; Hara T; Tsuchiya S; Agematsu K; Yamada M; Kawamura N; Ariga T; Tsuge I; Nonoyama S; Karasuyama H; Minegishi Y
    J Exp Med; 2011 Feb; 208(2):235-49. PubMed ID: 21300911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Manifestations and Genetic Analysis of 17 Patients with Autosomal Dominant Hyper-IgE Syndrome in Mainland China: New Reports and a Literature Review.
    Wu J; Chen J; Tian ZQ; Zhang H; Gong RL; Chen TX; Hong L
    J Clin Immunol; 2017 Feb; 37(2):166-179. PubMed ID: 28197791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes.
    Freeman AF; Holland SM
    Pediatr Res; 2009 May; 65(5 Pt 2):32R-37R. PubMed ID: 19190525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern.
    Boos AC; Hagl B; Schlesinger A; Halm BE; Ballenberger N; Pinarci M; Heinz V; Kreilinger D; Spielberger BD; Schimke-Marques LF; Sawalle-Belohradsky J; Belohradsky BH; Przybilla B; Schaub B; Wollenberg A; Renner ED
    Allergy; 2014 Jul; 69(7):943-53. PubMed ID: 24898675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Potential and Limits of Hematopoietic Stem Cell Transplantation for the Treatment of Autosomal Dominant Hyper-IgE Syndrome.
    Yanagimachi M; Ohya T; Yokosuka T; Kajiwara R; Tanaka F; Goto H; Takashima T; Morio T; Yokota S
    J Clin Immunol; 2016 Jul; 36(5):511-6. PubMed ID: 27091139
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.